Created

Sep 13, 2023 1:43 AM

Type

patent

Publication

Summary

This document describes a stabilized hypochlorous acid solution and its use, which may have applications in antimicrobial treatments and wound healing.

Key Points

- An antimicrobial solution has been developed that can be used to treat or prevent infections associated with abdominal surgery. - The solution contains hypochlorous acid, a divalent cation (such as calcium or magnesium), a phosphate anion, and chloride ion. - The specific dosage level for any particular patient will depend upon a variety of factors, including the strength of the antimicrobial solution, the severity of the condition, the patient's body weight, age, physical and mental condition, and more. - The solution has been tested against various bacteria and fungi, including MRSA, E. coli, and Candida albicans, and has shown significant reductions in their populations. - The stability of the solution has been shown to be good, with a small drop in pH observed over time. - The patent application includes a number of claims related to the composition and production of the antimicrobial solution.

super:Link

https://patents.google.com/patent/US20160120183A1/en

Date

Notes

Attachment

Source

This is from US20160120183A1 patent in 2018 at https://patents.google.com/patent/US20160120183A1/en.

Keywords

The top five keywords for this document are: stabilized hypochlorous acid, solution, patent, Sonoma Pharmaceuticals Inc, Oculus Innovative Sciences Inc.

Created time

Sep 13, 2023 1:43 AM

Stabilized hypochlorous acid solution and use thereof Download PDF

Info

Publication number US20160120183A1 US14/893,448 US201414893448A US2016120183A1 US 20160120183 A1 US20160120183 A1 US 20160120183A1 US 201414893448 A US201414893448 A US 201414893448A US 2016120183 A1 US2016120183 A1 US 2016120183A1 Authority Prior art keywords Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Granted

Application number

Other versions

Inventor

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sonoma Pharmaceuticals Inc

Original Assignee

Oculus Innovative Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Filing date

Publication date

Priority claimed from US201361826382P external-priority

2014-05-22 Application filed by Oculus Innovative Sciences Inc filed Critical Oculus Innovative Sciences Inc

2014-05-22 Priority to US14/893,448 priority Critical patent/US9918477B2/en

2015-11-24 Assigned to OCULUS INNOVATIVE SCIENCES, INC. reassignment OCULUS INNOVATIVE SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NORTHEY, ROBERT

2016-05-05 Publication of US20160120183A1 publication Critical patent/US20160120183A1/en

2017-01-05 Assigned to SONOMA PHARMACEUTICALS, INC. reassignment SONOMA PHARMACEUTICALS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: OCULUS INNOVATIVE SCIENCES, INC.

2018-03-20 Application granted granted Critical

2018-03-20 Publication of US9918477B2 publication Critical patent/US9918477B2/en

Status Active legal-status Critical Current

2034-05-22 Anticipated expiration legal-status Critical

Links

QWPPOHNGKGFGJK-UHFFFAOYSA-N Hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 45
230000000845 anti-microbial Effects 0.000 claims abstract description 65
-1 phosphate anion Chemical class 0.000 claims abstract description 50
239000010452 phosphate Substances 0.000 claims abstract description 40
238000000034 method Methods 0.000 claims abstract description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
150000001768 cations Chemical class 0.000 claims abstract description 26
238000001356 surgical procedure Methods 0.000 claims abstract description 24
201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 16
230000003187 abdominal Effects 0.000 claims abstract description 14
239000004599 antimicrobial Substances 0.000 claims abstract description 12
241000124008 Mammalia Species 0.000 claims abstract description 9
238000004519 manufacturing process Methods 0.000 claims abstract description 6
239000000243 solution Substances 0.000 claims description 151
239000000203 mixture Substances 0.000 claims description 32
VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 19
CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 19
KZBUYRJDOAKODT-UHFFFAOYSA-N chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 12
FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
239000011777 magnesium Substances 0.000 claims description 12
229910052749 magnesium Inorganic materials 0.000 claims description 12
229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
235000019341 magnesium sulphate Nutrition 0.000 claims description 9
229910000403 monosodium phosphate Inorganic materials 0.000 claims description 9
235000019799 monosodium phosphate Nutrition 0.000 claims description 9
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 9
OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
239000011575 calcium Substances 0.000 claims description 8
229910052791 calcium Inorganic materials 0.000 claims description 8
239000003002 pH adjusting agent Substances 0.000 claims description 8
241000588724 Escherichia coli Species 0.000 claims description 5
206010022017 Inguinal hernias Diseases 0.000 claims description 5
241000222122 Candida albicans Species 0.000 claims description 4
240000007639 Nepenthes mirabilis Species 0.000 claims description 4
241000607715 Serratia marcescens Species 0.000 claims description 4
238000007486 appendectomy Methods 0.000 claims description 4
238000002357 laparoscopic surgery Methods 0.000 claims description 4
238000002350 laparotomy Methods 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
241000194033 Enterococcus Species 0.000 claims description 3
MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 3
108010059993 Vancomycin Proteins 0.000 claims description 3
229960003165 Vancomycin Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims 1
239000011780 sodium chloride Substances 0.000 description 20
210000000683 Abdominal Cavity Anatomy 0.000 description 17
238000002360 preparation method Methods 0.000 description 15
230000001603 reducing Effects 0.000 description 14
238000006722 reduction reaction Methods 0.000 description 14
150000003839 salts Chemical class 0.000 description 14
239000000969 carrier Substances 0.000 description 9
244000005700 microbiome Species 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000003139 buffering Effects 0.000 description 6
210000004027 cells Anatomy 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000000460 chlorine Substances 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
108010013639 Peptidoglycan Proteins 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
210000001519 tissues Anatomy 0.000 description 4
206010003997 Bacteraemia Diseases 0.000 description 3
210000004369 Blood Anatomy 0.000 description 3
206010067410 Endotoxaemia Diseases 0.000 description 3
241000192125 Firmicutes Species 0.000 description 3
210000000936 Intestines Anatomy 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
239000008280 blood Substances 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000000249 desinfective Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000005868 electrolysis reaction Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
239000005020 polyethylene terephthalate Substances 0.000 description 3
229920000139 polyethylene terephthalate Polymers 0.000 description 3
231100000486 side effect Toxicity 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
230000004797 therapeutic response Effects 0.000 description 3
206010070545 Bacterial translocation Diseases 0.000 description 2
206010016825 Flushing Diseases 0.000 description 2
206010022114 Injury Diseases 0.000 description 2
239000004698 Polyethylene (PE) Substances 0.000 description 2
150000008044 alkali metal hydroxides Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000004059 degradation Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
239000004700 high-density polyethylene Substances 0.000 description 2
230000000968 intestinal Effects 0.000 description 2
229920001684 low density polyethylene Polymers 0.000 description 2
239000004702 low-density polyethylene Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
230000000717 retained Effects 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
241000894007 species Species 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
230000001954 sterilising Effects 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000001225 therapeutic Effects 0.000 description 2
210000001015 Abdomen Anatomy 0.000 description 1
229920000122 Acrylonitrile butadiene styrene Polymers 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
230000036912 Bioavailability Effects 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
210000001072 Colon Anatomy 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
230000036826 Excretion Effects 0.000 description 1
241000233866 Fungi Species 0.000 description 1
210000000232 Gallbladder Anatomy 0.000 description 1
210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
206010018987 Haemorrhage Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010061255 Ischaemia Diseases 0.000 description 1
210000000265 Leukocytes Anatomy 0.000 description 1
229940061634 Magnesium sulfate heptahydrate Drugs 0.000 description 1
RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
206010028154 Multi-organ failure Diseases 0.000 description 1
210000004303 Peritoneum Anatomy 0.000 description 1
206010034674 Peritonitis Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic shock Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
231100000765 Toxin Toxicity 0.000 description 1
241000700605 Viruses Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000240 adjuvant Effects 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
230000001580 bacterial Effects 0.000 description 1
244000052616 bacterial pathogens Species 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000035514 bioavailability Effects 0.000 description 1
230000000740 bleeding Effects 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000002561 chemical irritant Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002192 cholecystectomy Methods 0.000 description 1
150000001925 cycloalkenes Chemical class 0.000 description 1
238000005202 decontamination Methods 0.000 description 1
230000003588 decontaminative Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000020828 fasting Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
239000011888 foil Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001771 impaired Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000004207 intestinal integrity Effects 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000004707 linear low-density polyethylene Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000003340 mental Effects 0.000 description 1
230000002503 metabolic Effects 0.000 description 1
229960003085 meticillin Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000006011 modification reaction Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000474 nursing Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000003285 pharmacodynamic Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
BBMHARZCALWXSL-UHFFFAOYSA-M sodium;dihydrogen phosphate;hydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
231100000803 sterility Toxicity 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
108020003112 toxins Proteins 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

A—HUMAN NECESSITIES
A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K33/00—Medicinal preparations containing inorganic active ingredients
A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/02—Inorganic compounds

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/04—Antibacterial agents

A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/10—Antimycotics

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed is an antimicrobial solution comprising, consisting essentially of or consisting of (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water, as well as a process for its production. Also disclosed is a method of treating or preventing infection associated with abdominal surgery on a mammal, comprising use of the antimicrobial solution.

Description

In human patients undergoing abdominal surgery, Gram-positive bacteria and/or Gram-negative bacteria, which are normally present in the intestine, can cross the intestinal wall and reach the circulation. During surgery and/or preceding surgery, conditions such as fasting and ischaemia can be present which facilitate the bacterial translocation. In addition, the surgical procedure itself may result in a disrupted intestinal barrier, particularly during abdominal surgery. This translocation results in short and midterm complications including sepsis, bacteraemia, and endotoxaemia. Peritonitis, which is an inflammation of the peritoneum, also can result as a consequence of infection by microorganisms residing within the intestines which can be released during a surgical procedure.
Sepsis (or septic shock or septicemia) is a disorder which occurs when a relatively large amount of micro-organisms, or fragments thereof, enter the body. It is characterized as a systemic disease associated with the presence and persistence of pathogenic micro-organisms or their toxins in the blood. The presence of endotoxins, such as lipopolysaccharide (LPS), lipoteichoic acid (LTA) and/or peptidoglycan (PG), in the blood gives rise to a condition known as endotoxaemia or endotoxic shock. When the micro-organisms which have entered the blood are viable, this condition is also referred to as bacteraemia.
The intestine, especially the colon and the lower part of the small intestine, is a reservoir of LPS and Gram-negative bacteria, such as the common inhabitant Escherichia coli, but also of LTA, PG and Gram-positive bacteria. The presence of Gram-negative and/or gram-positive bacteria and/or LPS and/or LTA and/or PG in the gut does not create any issues for a healthy individual. However, upon increase of the intestinal permeability or decrease of the intestinal integrity during or after surgery, this can become a problem. Sepsis, bacteraemia and/or endotoxaemia lead to a prolonged hospital stay and thus increased costs and increased morbidity. It can also lead to multiple organ failure or even death. It is, therefore, of great importance to find a method to treat, and especially to prevent bacterial translocation and resulting infection during or shortly after surgery.
The invention provides an antimicrobial solution comprising (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water. The invention also provides a process for the production of an antimicrobial solution comprising the steps of (i) providing a mixture comprising (a) a divalent cation, (b) a phosphate anion, (c) a pH-adjusting agent, and (d) water, and (ii) adding chlorine gas to the mixture. The invention additionally provides a method of treating or preventing infection associated with abdominal surgery on a mammal, comprising administering to the mammal an effective amount of an antimicrobial solution comprising (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water.
The invention provides an antimicrobial solution comprising, consisting essentially of, or consisting of (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water.
The solution contains hypochlorous acid. The hypochlorous acid can be prepared using any suitable process. In an embodiment, the hypochlorous acid can be prepared by adding chlorine to water. In other embodiments, the hypochlorous acid can be prepared via electrochemical generation from an aqueous sodium chloride solution. In these embodiments, the hypochlorous acid can be prepared in a batch mode using a single chamber electrolysis cell, or the hypochlorous acid can be prepared in a continuous mode using a two- or three-chambered electrolysis cell. Examples of suitable three-chambered electrolysis cells are disclosed in U.S. Patent Application Publications 2005/0139808 A1 and 2005/0142157 A1, the disclosure of which are incorporated totally herein by reference.
The solution can contain any suitable amount of hypochlorous acid. The solution can contain about 10 mg/L or more, about 20 mg/L or more, about 30 mg/L or more, about 40 mg/L or more, about 50 mg/L or more, about 60 mg/L or more, about 70 mg/L or more, about 80 mg/L or more, about 90 mg/L or more, or about 100 mg/L or more of hypochlorous acid. Alternatively, or in addition, the solution can contain about 500 mg/L or less, about 450 mg/L or less, about 400 mg/L or less, about 350 mg/L or less, about 300 mg/L or less, about 250 mg/L or less, about 200 mg/L or less, or about 150 mg/L or less of hypochlorous acid. Thus, the solution can contain hypochlorous acid in an amount bounded by any two of the aforementioned endpoints. For example, the solution can contain about 10 mg/L to about 500 mg/L, about 10 mg/L to about 400 mg/L, about 10 mg/L to about 300 mg/L, about 10 mg/L to about 200 mg/L, about 20 mg/L to about 200 mg/L, about 30 mg/L to about 200 mg/L, about 40 mg/L to about 200 mg/L, about 50 mg/L to about 200 mg/L, about 50 mg/L to about 150 mg/L, or about 100 mg/L to about 150 mg/L of hypochlorous acid.
The solution contains a divalent cation. In certain embodiments, the divalent cation is magnesium, calcium, or a combination thereof. In certain embodiments, the divalent cation is magnesium. In certain embodiments, the divalent cation is calcium. In certain preferred embodiments, the divalent cation is magnesium.
The divalent cation can be provided as a component of any suitable compound. In certain embodiments, the divalent cation is a component of a salt. The salt can be any suitable salt. For example, the salt may comprise the divalent cation as the cationic component thereof and an anionic component selected from sulfate, nitrate, hydroxide, carbonate, hydrogencarbonate, halide (e.g., chloride, bromide, iodide, or fluoride), sulfonate, alkylsulfonate, and the like. In certain preferred embodiments, the salt comprises sulfate as the anionic component. In certain more preferred embodiments, the salt is magnesium sulfate or calcium sulfate, or a combination thereof
The solution can contain any suitable amount of the divalent cation. The solution can contain about 20 mg/L or more, about 30 mg/L or more, about 40 mg/L or more, about 50 mg/L or more, about 60 mg/L or more, about 70 mg/L or more, about 80 mg/L or more, about 90 mg/L or more, or about 100 mg/L or more of the divalent cation. Alternatively, or in addition, the solution can contain about 250 mg/L or less, about 225 mg/L or less, about 200 mg/L or less, about 175 mg/L or less, about 150 mg/L or less, or about 250 mg/L or less, about 200 mg/L or less, or about 150 mg/L or less of the divalent cation.
Accordingly, the solution can contain the divalent cation in an amount bounded by any two of the aforementioned endpoints. For example, the solution can contain about 20 mg/L to about 250 mg/L, about 20 mg/L to about 225 mg/L, about 20 mg/L to about 200 mg/L, about 20 mg/L to about 175 mg/L, about 20 mg/L to about 150 mg/L, about 30 mg/L to about 200 mg/L, about 40 mg/L to about 200 mg/L, about 50 mg/L to about 200 mg/L, about 50 mg/L to about 150 mg/L, about 75 mg/L to about 125 mg/L, or about 100 mg/L to about 150 mg/L of the divalent cation.
The solution contains phosphate anion. The phosphate anion can be provided using any suitable source of phosphate anion. As is well known in the art, phosphate anions are derived from phosphorous acid and can be phosphate anion (PO ), hydrogenphosphate anion (HPO ), or dihydrogenphosphate anion (HPO). The phosphate anion can be provided as a component of any suitable compound. In certain embodiments, the phosphate anion is a component of a salt. The salt can be any suitable salt. For example, the salt may comprise the phosphate anion as the anionic component thereof and a cationic component selected from alkali metal (e.g., Li, Na, K), ammonium, and the like. In certain preferred embodiments, the salt comprises sodium as the cationic component. In certain more preferred embodiments, the salt is sodium dihydrogen phosphate. The salt can be anhydrous or can be a hydrate (e.g., sodium dihydrogen phosphate monohydrate).

3−

2−

4−

The solution can contain any suitable amount of the phosphate anion. In this regard, the amount of phosphate anion is calculated on the basis of phosphate anion formulated as PO . Thus, for example, the amount of the source of phosphate anion used in the antimicrobial solution is calculated to provide the amount of phosphate anion formulated as PO as recited herein. The solution can contain about 200 mg/L or more, about 220 mg/L or more, about 240 mg/L or more, about 260 mg/L or more, about 280 mg/L or more, about 300 mg/L or more, about 320 mg/L or more, about 340 mg/L or more, about 360 mg/L or more, about 380 mg/L or more, or about 400 mg/L or more of the phosphate anion. Alternatively, or in addition, the solution can contain about 1000 mg/L or less, about 900 mg/L or less, about 800 mg/L or less, about 700 mg/L or less, about 600 mg/L or less, about 580 mg/L or less, about 560 mg/L or less, about 540 mg/L or less, about 520 mg/L or less, or about 500 mg/L or less, about 480 mg/L or less, about 460 mg/L or less, about 440 mg/L or less, about 420 mg/L or less, or about 400 mg/L or less of the phosphate anion.

3−

Accordingly, the solution can contain the phosphate anion in an amount bounded by any two of the aforementioned endpoints. For example, the solution can contain about 200 mg/L to about 1000 mg/L, about 200 mg/L to about 900 mg/L, about 200 mg/L to about 800 mg/L, about 200 mg/L to about 700 mg/L, about 200 mg/L to about 600 mg/L, about 200 mg/L to about 580 mg/L, about 200 mg/L to about 560 mg/L, about 200 mg/L to about 540 mg/L, about 200 mg/L to about 520 mg/L, about 200 mg/L to about 500 mg/L, or about 300 mg/L to about 500 mg/L of the phosphate anion.
The solution optionally further comprises chloride ion. The chloride ion can be provided by any suitable source of chloride ion. For example, the chloride ion can be provided in the form of an added salt. In certain embodiments, the hypochlorous acid is generated in situ by the addition of chlorine gas to water. The chlorine gas reacts with water to produce hypochlorous acid and one equivalent of chloride ion in the form of hydrochloric acid: Cl+H2O→HOCl+HCl.

The solution can contain any suitable amount of chloride ion. The solution can contain about 10 mg/L or more, about 20 mg/L or more, about 30 mg/L or more, about 40 mg/L or more, about 50 mg/L or more, about 60 mg/L or more, about 70 mg/L or more, about 80 mg/L or more, about 90 mg/L or more, or about 100 mg/L or more of chloride ion. Alternatively, or in addition, the solution can contain about 300 mg/L or less, about 280 mg/L or less, about 260 mg/L or less, about 240 mg/L or less, about 220 mg/L or less, or about 200 mg/L or less of chloride ion. Thus, the solution can contain chloride ion in an amount bounded by any two of the aforementioned endpoints. For example, the solution can contain about 10 mg/L to about 300 mg/L, about 20 mg/L to about 280 mg/L, about 30 mg/L to about 260 mg/L, about 40 mg/L to about 240 mg/L, about 50 mg/L to about 220 mg/L, or about 60 mg/L to about 200 mg/L of chloride ion.
The solution has a pH of about 3 or more, about 3.5 or more, or about 4.5 or more. Alternatively, or in addition, the solution has a pH of about 7 or less, about 6.5 or less, about 6 or less, or about 5.5 or less. Thus, the solution can have a pH bounded by any two of the aforementioned endpoints. For example, the solution can have a pH of about 3 to about 7, about 3 to about 6.5, about 3 to about 6, about 3 to about 5.5, about 3.5 to about 7, about 3.5 to about 6.5, about 3.5 to about 6, about 3.5 to about 5.5, about 4 to about 7, about 4 to about 6.5, about 4 to about 6, about 4 to about 5.5, about 4.5 to about 7, about 4.5 to about 6.5, about 4.5 to about 6, or about 4.5 to about 5.5.
The solution optionally comprises a compound capable of adjusting and/or buffering the pH. The compound capable of adjusting and/or buffering the pH can be selected from the group consisting of alkali metal salts, carboxylic acids, alkali metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, borates, and mixtures thereof. In certain preferred embodiments, the compound capable of adjusting and/or buffering the pH is an alkali metal hydroxide, for example, sodium hydroxide.
In certain preferred embodiments, the solution comprises (a) about 10 mg/L to about 500 mg/L of hypochlorous acid, (b) magnesium sulfate in an amount sufficient to provide about about 20 mg/L to about 250 mg/L of magnesium, (c) sodium dihydrogen phosphate is present in an amount sufficient to provide about 200 mg/L to about 1000 mg/L of phosphate anion formulated as PO , (d) about 20 mg/L to about 100 mg/L of chloride ion, and (e) water, wherein the solution has a pH of about 3 to about 7.

2−

It is believed that the phosphate anion can provide buffering of the pH of the antimicrobial solution to a preferred pH range. However, a significant amount of phosphate anion is required to exhibit buffering activity at this pH range. It is known that phosphate anion increases the degradation rate of hypochlorous acid. It has been unexpectedly found that the combination of divalent cation and phosphate anion allows for a reduction in the amount of phosphate anion required to provide a buffering action and further exhibits a significantly reduced rate of hypochlorous acid degradation.
The antimicrobial solution of the present invention is generally stable for at least twenty-hours, and typically at least two days. More typically, the solution is stable for at least one week (e.g., one week, two weeks, three weeks, four weeks, etc.), and preferably at least two months. More preferably, the solution is stable for at least six months after its preparation. Even more preferably, the solution is stable for at least one year, and most preferably for at least three years.
As used herein, the term stable generally refers to the ability of the antimicrobial water solution to remain suitable for its intended use, for example, in surgical applications, decontamination, disinfection, sterilization, anti-microbial cleansing, and wound cleansing, for a specified period of time after its preparation under normal storage conditions (i.e., room temperature). In this regard, the antimicrobial solution of the present invention is also stable when stored under accelerated conditions, typically about 30° C. to about 60° C., for at least 90 days, and preferably 180 days.
The concentrations of ionic and other species present in solution are generally maintained during the shelf-life of the antimicrobial solution. Typically, the concentration of hypochlorous acid is maintained at about 70% or greater from its initial concentration for at least two months after preparation of the antimicrobial solution. Preferably, this concentration is maintained at about 80% or greater of its initial concentration for at least two months after preparation of the solution. More preferably, this concentration is at about 90% or greater of ita initial concentration for at least two months after preparation of the solution, and most preferably, about 95% or greater.
The stability of the antimicrobial solution of the present invention may be determined based on the reduction in the amount of live microorganisms present in a sample following exposure to the solution. The measurement of the reduction of organism concentration may be carried out using any suitable organism including bacteria, fungi, yeasts, or viruses, as described herein. The low pH antimicrobial solution is useful as both a low-level disinfectant capable of a four log (10) reduction in the concentration of live microorganisms and a high-level disinfectant capable of a six log (10) reduction in concentration of live microorganisms.

In one embodiment of the present invention, the antimicrobial solution is capable of yielding at least a four log (10) reduction in total organism concentration following exposure for one minute, when measured at least two months after preparation of the solution. Preferably, the solution is capable of such a reduction of organism concentration when measured at least six months after preparation of the solution. More preferably, the solution is capable of such a reduction of organism concentration when measured at least one year after preparation, and most preferably when measured at least three years after preparation.

In another embodiment the present invention, the antimicrobial solution is capable of yielding at least a six log (10) reduction in total organism concentration within one minute of exposure, when measured at least two months after preparation of the solution. Preferably, the solution is capable of achieving this reduction when measured at least six months after preparation, and more preferably at least one year after preparation. Preferably, the solution is capable of at least a seven log (10) reduction in the concentration of live microorganisms within one minute of exposure, when measured at least two months after preparation.

The invention also provides a pharmaceutical composition comprising the antimicrobial solution and a pharmaceutically acceptable carrier. The antimicrobial solution can be administered alone or in combination with one or more pharmaceutically acceptable carriers, e.g., vehicles, adjuvants, excipients, diluents, combinations thereof, and the like, which are preferably compatible with one or more of the species that exist in the antimicrobial solution. One skilled in the art can easily determine the appropriate formulation and method for administering the antimicrobial solution used in accordance with the present invention. For instance, the use of a gel based formulation containing the antimicrobial solution can be used to maintain hydration of the abdominal cavity while providing a barrier against microorganisms. Suitable gel formulations are described, e.g., in U.S. Patent Application Publication No. US 2005/0142157 A1 (hereby incorporated by reference). Any necessary adjustments in dose can be readily made by a skilled practitioner to address the nature and/or severity of the condition being treated in view of one or more clinically relevant factors, such as, e.g., side effects, changes in the patient's overall condition, and the like.
For example, the antimicrobial solution can be formulated by combining or diluting the HOCl water solution with about 25% (wt./wt. or vol./vol.) of a suitable carrier, about 50% (wt./wt. or vol./vol.) of a suitable carrier, about 75% (wt./wt. or vol./vol.) of a suitable carrier, about 90% (wt./wt. or vol./vol.) of a suitable carrier, about 95% (wt./wt. or vol./vol.) of a suitable carrier, or even with about 99% (wt./wt. or vol./vol.) or more of a suitable carrier. Suitable carriers can include, e.g., water (e.g., distilled water, sterile water, e.g., sterile water for injection, sterile saline and the like). Suitable carriers also can include one or more carriers described in U.S. patent application Ser. No. 10/916,278 (hereby incorporated by reference). Exemplary formulations can include, e.g., solutions in which the antimicrobial solution is diluted with sterile water or sterile saline, wherein the antimicrobial solution is diluted by about 25% (vol./vol.), by about 50% (vol./vol.), by about 75% (vol./vol.), by about 90% (vol./vol.), by about 95% (vol./vol.), or by 99% (vol./vol.) or more, depending on the therapeutic application and/or any other therapeutically relevant factors.
The antimicrobial solution and pharmaceutical compositions comprising the same can be sterilized prior to or after packaging. For example, the sterilization can be carried out by autoclaving at an elevated temperature for a period of time (e.g., at 121° C. for 40 min).
The invention also provides a process for the production of an antimicrobial solution comprising the steps of (i) providing a mixture comprising (a) a divalent cation, (b) a phosphate anion, (c) a pH-adjusting agent, and (d) water, and (ii) adding chlorine gas to the mixture. The components can be provided in any order. For example the divalent cation, phosphate anion, pH-adjusting agent, and water can be combined in any order. The chlorine gas can be added to the mixture before, during, or after the addition of any other of the components. Optional chloride ion can be added at any stage of the process. As discussed herein, chlorine gas reacts with water to produce hypochlorous acid and hydrochloric acid. Hydrochloric acid reacts with the pH-adjusting agent to produce water and chloride ions. In an embodiment, the chlorine gas is bubbled into the solution, either prior to addition of the additional components, after addition of one or more of the additional components, or after addition of all of the additional components.
The process can be carried out in a batch mode or in a continuous mode. For example, the process can be carried out in a flow apparatus in which the components of the solution can be added in the form of solutions, while chlorine gas is bubbled into the flow stream. Alternatively, the chlorine gas can be added to water, and the resulting solution introduced into the flow apparatus at any suitable point.
In another embodiment, the invention provides a process for the production of an antimicrobial solution comprising the steps of (i) providing a mixture comprising hypochlorous acid and water, and (ii) adding (a) a divalent cation, (b) a phosphate anion, and (c) a pH-adjusting agent to the mixture.
The hypochlorous acid can be prepared using any suitable process as discussed herein in connection with the inventive antimicrobial solution. In an embodiment, the hypochlorous acid can be prepared by adding chlorine to water. In other embodiments, the hypochlorous acid can be prepared via electrochemical generation from an aqueous sodium chloride solution using a single chamber cell or using two- and three-chambered cells. In some embodiments, arrangements comprising multiple cells can be utilized to provide the hypochlorous acid.
The other components, i.e., the divalent cation, the phosphate anion, and the pH-adjusting agent, and compounds comprising the aforesaid components, can be provided in the form of solids or in the form of solutions comprising the aforesaid components. The components may be mixed using any suitable method capable of incorporating the components into the solution. For example, a mixture comprising the components may be stirred in a vessel for a time sufficient to incorporate the components into the solution.
Following its preparation, the antimicrobial solution of the present invention may be transferred to a sealed container for distribution and sale to end users such as, for example, health care facilities including hospitals, nursing homes, doctor offices, outpatient surgical centers, dental offices, and the like. Any suitable sealed container may be used that maintains the sterility and stability of the antimicrobial solution held by the container. The container may be constructed of any material that is compatible with the solution and should be generally non-reactive so that the ions present in the solution do not react with the container to any appreciable extent.
Preferably, the container is constructed of plastic or glass. The plastic may be rigid so that the container is capable of being stored on a shelf. Alternatively, plastic may be flexible, such as a flexible bag.
Suitable plastics include polypropylene, polyethylene terephthalate (PET), polyolefin, cycloolefin, polycarbonate, ABS resin, polyethylene, polyvinyl chloride, and mixtures thereof. Preferably, the container comprises polyethylene selected from the group consisting of high-density polyethylene (HDPE), low-density polyethylene (LDPE), and linear low-density polyethylene (LLDPE). Most preferably, the container is high density polyethylene or polyethylene terephthalate.
The container has an opening to permit dispensing of the low pH antimicrobial solution. The container opening may be sealed in any suitable manner. For example, the container may be sealed with a twist-off cap or stopper. Optionally, the opening may be further sealed with a foil layer.
The antimicrobial solution can be provided in the form of a kit comprising the antimicrobial solution, by itself or in the form of a composition comprising the same, and further including instructions for the use thereof
The invention also provides a method of treating or preventing infection associated with abdominal surgery on a mammal, comprising administering to the mammal an effective amount of the antimicrobial solution or the pharmaceutical composition as described herein. In certain embodiments, the surgery is inguinal hernia surgery, exploratory laparotomy, appendectomy, or laparoscopy.
The term abdominal surgery broadly covers surgical procedures that involve opening the abdomen. The most common abdominal surgeries include inguinal hernia surgery, exploratory laparotomy, appendectomy, and laparoscopy. Inguinal hernia surgery refers to the repair of an inguinal hernia. Exploratory laparotomy refers to the opening of the abdominal cavity for direct examination of the contents thereof, for example, to locate a source of bleeding or the location of a trauma. The procedure may or may not be followed by repair or removal of the source of the primary problem. Appendectomy refers to surgical opening of the abdominal cavity and removal of the appendix. Laparoscopy refers to a minimally invasive approach to abdominal surgery wherein tubes and other instruments are inserted into the abdominal cavity via small incisions. The most common laparoscopic procedure is cholecystectomy (gallbladder removal), but many other procedures are also performed using laparascopic techniques, for example, various gynecological procedures.
Advantageously, use of the inventive antimicrobial solution during abdominal surgery prevents or treats infection associated with abdominal surgery.
In accordance with certain embodiments, a therapeutically effective amount of the antimicrobial solution can be administered by delivering the antimicrobial solution to the abdominal cavity using any suitable delivery method, to treat or prevent infections. A therapeutically effective amount of the antimicrobial can be delivered to the patient's abdominal cavity intra-operatively, laproscopically, or transabdominally. The antimicrobial solution can be delivered, e.g., to peritoneal tissue susceptible for developing an infection (e.g., as a result of surgery, laparoscopic-diagnostic procedures, injury, infection, disease, allergic reaction, contact with one or more chemical irritants, or proximity to impaired, damaged and/or infected tissue, and the like).
Abdominal lavage, e.g., repeated flushings of the abdominal cavity, with the antimicrobial solution can be used to perform the method of the present invention. The antimicrobial solution can be retained in the abdominal cavity for any suitable length of time, e.g., a period of time effective to provide a therapeutic response, which can be seconds, minutes, hours, or days. In one embodiment, the present invention provides a method of treating or preventing infection, which method includes gaining access to the abdominal space, e.g., surgically or transabdominally; delivering to the patient's abdominal cavity of a therapeutically effective amount of the antimicrobial solution, e.g., about 1-10 liters, allowing the water to remain in the abdominal cavity for a period of time sufficient to effectuate a therapeutic response, e.g., seconds, minutes, or hours; optionally removing the antimicrobial solution from the abdominal cavity; optionally, removing the antimicrobial solution from the abdominal cavity; optionally, delivering saline or other physiologic solution prior or after delivering the antimicrobial solution; and optionally, repeating the abdominal lavage for as many times as necessary.
A therapeutically effective amount of the antimicrobial solution can be delivered to the abdominal cavity, e.g., by gravity (e.g., by pouring or dispensing the antimicrobial solution from a container or device) or by delivering the antimicrobial solution under pressure (e.g., by spraying). One or more flushings of the abdominal cavity can be performed, i.e., the abdominal cavity can be “lavaged.” The antimicrobial solution can be retained in the abdominal cavity for any suitable length of time, e.g., a period of time effective to provide a therapeutic response, e.g., seconds, minutes, hours, or days, and optionally removed using any suitable method. Suitable methods of removal can include, e.g., allowing the antimicrobial solution to be naturally absorbed into one or more surrounding tissues, blotting with one or more absorbent materials (e.g., gauze, sponge, towel, or mesh), removal by suction, and the like, and combinations thereof
The inventive method can treat or prevent infection caused by any suitable microorganism. In certain embodiments, the inventive method treats or prevents infection caused by an organism selected from methicilln-resistant S. aureus, E. coli, P. aeruginosa, Vancomycin-resistant Enterococcus, P. mirabilis, S. marcescens, and C. albicans.
A surgeon can assess the effectiveness of the treatment using methods commonly known in the art. For example, a surgeon or other physician can perform examination of fluids or tissues obtained from the abdominal cavity for the presence of absence of infections microorganisms. In other embodiments, the surgeon or physician can assess the mammal for secondary indications of infection such as, increased body temperature, increase in white blood cell count, and the like.
The therapeutically effective amount administered to the patient, e.g., a mammal, particularly a human, in the context of the present invention should be sufficient to affect a therapeutic or prophylactic response in the patient over a reasonable time frame. The dose can be readily determined using methods that are well known in the art. One skilled in the art will recognize that the specific dosage level for any particular patient will depend upon a variety of potentially therapeutically relevant factors. For example, the dose can be determined based on the strength of the particular antimicrobial solution employed, the severity of the condition, the body weight of the patient, the age of the patient, the physical and mental condition of the patient, general health, sex, diet, and the like. The size of the dose also can be determined based on the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular antimicrobial solution. It is desirable, whenever possible, to keep adverse side effects to a minimum.
Factors, which can be taken into account for a specific dosage can include, for example, bioavailability, metabolic profile, time of administration, route of administration, rate of excretion, the pharmacodynamics associated with a particular HOCl water solution in a particular patient, and the like. Other factors can include, e.g., the potency or effectiveness of the HOCl water solution with respect to the particular condition to be treated, the severity of the symptoms presented prior to, during or following the course of therapy, and the like. In some instances, what constitutes a therapeutically effective amount also can be determined, in part, by the use of one or more of the assays, e.g., bioassays, which are reasonably clinically predictive of the efficacy of a particular HOCl water solution for the treatment or prevention of a particular condition.
Process water was added to a reaction vessel. Next, sodium phosphate monobasic monohydrate, magnesium sulfate heptahydrate, and 5N sodium hydroxide were added. After stirring for a period of time to allow for mixing, chlorine gas was bubbled through the reaction mixture. The reaction mixture was monitored for the amount of chlorine present in the reaction mixture. Additional chlorine was added as necessary to achieve the target hypochlorous acid content. The pH of the reaction mixture was then adjusted by the addition of 5N sodium hydroxide to achieve a pH of 3.4-5.5.
Solutions A-F were prepared comprising about 106 mg/L of hypochlorous acid at a pH of 5.5 and having different amounts of sodium dihydrogenphosphate and magnesium sulfate as shown in Table 2. The solutions were aged in glass containers at 80° C. for 130 h. The pH drop was determined, and the results set forth in Table 2.

A	0.122	1.33	0.33
B	0.245	1.33	0.12
C	0.367	1.33	0.08
D	0.245	0.443	0.19
E	0.245	0.887	0.16
F	0.245	1.333	0.12

As is apparent from the results set forth in Table 2, increasing the amount of sodium dihydrogenphosphate from Solution A to Solution C at a constant level of magnesium sulfate reduced the pH drop of the solution from 0.33 to 0.08. Increasing the amount of magnesium sulfate from Solution D to Solution F at a constant level of sodium dihydrogenphosphate reduced the pH drop of the solution from 0.19 to 0.12. The small drop in pH observed for all of the solutions is indicative of the stability of the inventive antimicrobial solution.
An antimicrobial solution prepared in accordance with an embodiment of the invention was tested against methicillin-resistant S. aureus (MRSA), E. coli, P. aeruginosa, Vancomycin-resistant Enterococcus, P. mirabilis, S. marcescens, and C. albicans. The log reductions at contact times of 30 sec, 1 min, 2, min, 5 min, and 10 min were determined, and the results set forth in Table 3.

Bacteria	30 s	1 min	2 min	5 min	10 min	reduction	time (h)

MRSA	8.5	8.5	8.5	8.5	8.5	99.9999997	24.5
E. coli	8.4	8.4	8.4	8.4	8.4	99.9999996	24
P. aeruginosa	8.2	8.2	8.2	8.2	8.2	99.9999993	25
VRE	8.1	8.1	8.1	8.1	8.1	99.9999993	24
P. mirabilis	8.3	8.3	8.3	8.3	8.3	99.9999995	57
S. marcescens	8.8	8.8	8.8	8.8	8.8	99.9999999	24.5
C. albicans	7.1	7.1	7.1	7.1	7.1	99.9999929	22.5

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims (40)

1. An antimicrobial solution comprising:

(b) about 20 mg/L to about 250 mg/L of a divalent cation selected from calcium, magnesium, and a combination thereof,

3. The solution of claim 1, wherein the solution comprises about 50 mg/L to about 250 mg/L of hypochlorous acid.

7. The solution of claim 1, wherein the magnesium is provided by magnesium sulfate and the calcium is provided by calcium sulfate.

10. The solution of claim 1, wherein the phosphate anion is provided by sodium dihydrogen phosphate.

12. The solution of claim 1, wherein the solution further comprises about 10 mg/L to about 400 mg/L of chloride ion.

15. The solution of claim 1, wherein the solution comprises:

(c) sodium dihydrogen phosphate is present in an amount sufficient to provide about 200 mg/L to about 1000 mg/L of phosphate anion formulated as PO4 2−

17. A pharmaceutical composition comprising the solution of claim 1 and a pharmaceutically acceptable carrier.

18. A sealed container comprising the solution of claim 1, or the composition of claim 17.

20. A process for the production of an antimicrobial solution comprising the steps of:

(i) providing a mixture comprising (a) about 20 mg/L to about 250 mg/L of a divalent cation selected from magnesium, calcium, and a combination thereof, (b) about 200 mg/L to about 1000 mg/L of a phosphate anion formulated as PO4 2−, (c) a pH-adjusting agent, and (d) water, and

wherein the process produces a solution comprising hypochlorous acid in an amount from about 10 mg/L to about 500 mg/L and having a pH from about 3 to about 7.

24. The process of claim 20, wherein the process produces a solution comprising hypochlorous acid in an amount from about 50 mg/L to about 250 mg/L.

28. The process of claim 27, wherein the magnesium is provided by magnesium sulfate and the calcium is provided by calcium sulfate.

31. The process of claim 20, wherein the phosphate anion is provided by sodium dihydrogen phosphate.

33. The process of claim 20, wherein the solution further comprises about 20 mg/L to about 100 mg/L of chloride ion.

34. The process of claim 20, wherein the chlorine gas is bubbled into the buffer solution.

36. A process for the production of an antimicrobial solution comprising the steps of:

(ii) adding (a) about 20 mg/L to about 250 mg/L of a divalent cation selected from magnesium, calcium, and a combination thereof, (b) about 200 mg/L to about 1000 mg/L of a phosphate anion formulated as PO4 2−, and (c) a pH-adjusting agent to the mixture,,

wherein the process produces a solution comprising hypochlorous acid in an amount from about 10 mg/L to about 500 mg/L and having a pH from about 3 to about 7.

37. The process of claim 36, wherein the hypochlorous acid is electrochemically generated.

41. The process of claim 36, wherein the process produces a solution comprising hypochlorous acid in an amount from about 50 mg/L to about 250 mg/L.

45. The process of claim 36, wherein the magnesium is provided by magnesium sulfate and the calcium is provided by calcium sulfate.

48. The process of claim 36, wherein the phosphate anion is provided by sodium dihydrogen phosphate.

50. The process of claim 36, wherein the solution further comprises about 20 mg/L to about 100 mg/L of chloride ion.

51. A method of treating or preventing infection associated with abdominal surgery on a mammal, comprising administering to the mammal an effective amount of the solution of claim 1.

52. The method of claim 51, wherein the surgery is inguinal hernia surgery, exploratory laparotomy, appendectomy, or laparoscopy.

54. The method of claim 51, wherein the infection is caused by an organism selected from methicilln-resistant S. aureus, E. coli, P. aeruginosa, Vancomycin-resistant Enterococcus, P. mirabilis, S. marcescens, and C. albicans.

US14/893,448 2013-05-22 2014-05-22 Stabilized hypochlorous acid solution and use thereof Active US9918477B2 (en)

Priority Applications (1)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361826382P	2013-05-22	2013-05-22
PCT/US2014/039202 WO2014190184A1 (en)	2013-05-22	2014-05-22	Stabilized hypochlorous acid solution and use thereof
US14/893,448 US9918477B2 (en)	2013-05-22	2014-05-22	Stabilized hypochlorous acid solution and use thereof

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=51934166

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US14/893,448 Active US9918477B2 (en)	2013-05-22	2014-05-22	Stabilized hypochlorous acid solution and use thereof
US15/926,927 Active US10412969B2 (en)	2013-05-22	2018-03-20	Stabilized hypochlorous acid solution and use thereof